Abstract
It is more important that the chemotherapist should be able to prevent the complications of chemotherapy rather than to cure them. Each treatment used routinely whether by a cancerologist or a general practitioner should have previously been submitted to reliable therapeutic trials. This reliability should not only apply to the average patient, but also to the individual patient who might have cirrhosis of the liver or be taking barbiturates, both of which can influence the antitumour effects and the toxicity. Any new drug, if it is to be used in clinical trials by the cancerologist, ought to have been previously subjected to preclinical testing on animals using all the modern methods (see Mathé and Kenis, 1973, 1974).
But one must be able to evaluate if the patient will be strong enough with the “regimen” and anticipate whether the disease or the patient will succumb to the “regimen” first.
Hippocrates
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Breard, J., Weinerc R. Oldham R.: Immune restoration after chemotherapy and during active immunotherapy. This volume, p. 56.
Bruce, W. R.: The action of chemotherapeutic agents at the cellular level dans the effect of these agents on hematopoietic and leukaemic tissue. Canad. Cancer Conf. 7, 53 (1966).
BrunnerK. W., Marthaler TH. MullerW.: Unfavourable effects of long-term adjuvant chemotherapy with endoxan in radically operated bronchogenic carcinoma. Europ. J. Cancer 7, 285 (1971).
Devita V. T. Serpick, A. A., Carbone, P. P.: Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann. intern. Med. 73, 881 (1970).
E.O.R.T.C. Clinical screening of epipodophyllotoxin YM 26 in malignant lymphomas and solid tumours. Brit. med. J. 1972 I, 744.
E.O.R.T.C. Leukemia and Hematosarcoma Group. A comparative trial of remission induction (by cytosin arabinoside (CAR) or CAR and thioguanine, or CAR and daunorubicine) and maintenance therapy (by CAR or methylgag) in acute myeloid leukemia. Biomedicine, 18, 192 (1973).
Goldman, I. D., Fyfe, M. J.: Free intracellular methotrexate (MTX) is required for maximum inhibition of DNA synthesis-augmentation by vincristine (VCR). Proc. Amer. Ass. Cancer Res. 14, 50 (1973) (abstract 199).
Holland, J. F.: E pluribus unnum. Cancer Res. 31, 1319 (1971).
Mathé, G.: examination of drugs, a scientific and ethical challenge. Biomedicine 18, 169 (1973).
Mathé, G., Amiel, J. L., Schwarzenberg, L.: Bone marrow transplantation and leucocyte transfusions. 1 Vol. Springfield: C. C. Thomas, 1971.
Mathé, G. Berumen, L., Schweisguth, O., Brule G. Schneider, M., Cattan, A., Amiel J. L., Schwarzenberg, L.: Methyl-hydrazine in treatment of Hodgkin’s disease and various forms of hematosarcoma or leukemia. Cancer 2, 1077 (1963).
Mathé, G., ForestierP.: outil moderne de la recherche médicale française, l’Institut de Cancérologie et d’Immunogénétique. Intrications de la recherche expérimentale et clinique. Conditionnement hyposeptique des animaux et malades. Tech. Hosp. 20, 47 (1965).
Mathé, G., Kenis, Y.: Logistics of therapeutic trials: the example of cancerology. Biomedicine 18, 181 (1973).
Mathé, G., Kenis, Y.: La chimiothérapie des cancers (leucémies, hématosarcomes, tumeurs solides). 3rd ed., 1 Vol. Paris: Expansion Scientifique Française, 1974.
Mathé, G., Schneider, M. SchwarzenbergL.: time factor in cancer chemotherapy. Europ. J. Cancer 6, 23 (1970).
Mathé, G. SchwarzenbergL. Hayat, M., Schneider, M.: Chimiothérapie de la leucémie L1210. Comparaison, pour sept composés, des effets de l’administration continue sur 20 jours et de l’administration d’une dose massive unique, précoce ou tardive. Rev. franç. Étud. clin. blol. 13, 951 (1968).
Mathé, G., Schwarzenberg, L., Pouillart, P., Oldham, R., Weiner, R., Jasmin, C., Rosenfeld, C Hayat, M., Schneider, M., Amiel, J. L., de Vassal, F., Steresco-Musset, M.: Two epipodophyllotoxin derivatives VM 26 and VP 16213 in the treatment of leukemias and hematosarcomas. Cancer 1973, in press.
Mathé, G., Weiner , R.: Criteria for short term results in the treatment of acute leukemia. In: Acute leukemias nomenclature, classification, clinical trials, methodology and actuarial results. 1 Vol. Eds.: G. Mathé P. Pouillart, L. Schwarzenberg. Berlin-Heidelberg: Springer 1973.
Pauling, L.: Vitamin C and the common cold. 1 Vol., New York: Freeman 1971.
Pouillart, P., Hoang Thi HuongT.: Putting mouse cells into cycle (CFUs) by diverse agents: radiations, cytostatics, androgens and BCG. Exp. Haemat. 1973 (in press).
Pouillart, P., Schwarzenberg, L., Mathé, G., Schneider, M., Jasmin, C., Hayat, M., Weiner, R., de Vassal, F., Amiel, J. L., Beyer, H. P., Fajbisowicz, S.: Essai clinique de combinaisons diimiothérapiques basées sur la notion de tentative de synchronization cellulaire. Administration première d’un antimitotique suivie de l’application de produit(s) cycle ou phase dépendant(s). Nouv. Press, méd. 1, 1757 (1972).
Recent Results in Cancer Research, Vol. 1. Aseptic environments and cancer treatment. Ed.. G. Mathé. Heidelberg: Springer 1970.
SchneiderM.: des chimiothérapies antimitotiques sur une réaction d’hypersensibilité retardée. Rev. franç. Étud. clin, biol., 13, 877 (1968).
SchwarzenbergL., Cattan, A., Schneider, M., Schlumberger, J. R., Amiel, J. L., Mathé G.: Réanimation hématologique. I. Correction des troubles graves de la lignée érythrocytaire et des désordres de la coagulation. Presse méd. 74, 969 (1966).
Schwarzenberg, L., Cattan , A., Schneider, M., Schlumberger, J. R., Amiel, J. L., Mathé G.: Réanimation hématologique. II. Correction des désordres graves des leucocytes et des immunoglobulines. La greffe de moelle osseuse. Presse méd. 74, 1061 (1966).
Van PuttenL. M., Lelieveld, P.: Factors determining cell killing by chemotherapeutic agents in vivo. I. Cyclophosphamide. Europ. J. Cancer 6, 213 (1970).
VanputtenL. M., Lelieveld, P.: Factors determining cell killing by chemotherapeutic agents in vivo. II. Melphalan, chlorambucil and nitrogen mustard. Europ. J. Cancer 7, 11 (1971).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1974 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Mathé, G. (1974). Prevention of Chemotherapy Complications: Time, Toxicity, Pharmacokinetic, Pharmacodynamic and Logistic Factors. In: Mathé, G., Oldham, R.K. (eds) Complications of Cancer Chemotherapy. Recent Results in Cancer Research, vol 49. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80848-7_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-80848-7_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-80850-0
Online ISBN: 978-3-642-80848-7
eBook Packages: Springer Book Archive